Pharmaceutical Contract Development and Manufacturing Market Size, Share, Growth Analysis, By Service(Pharmaceutical Manufacture, Drug Development, And Biologics Manufacturing.), By End user(Large pharmaceutical firms, small & mid-size pharmaceutical companies, and generic pharmaceutical companies.), By Region - Industry Forecast 2025-2032

Pharmaceutical Contract Development and Manufacturing Market size was valued at USD 122.25 Billion in 2023 and is poised to grow from USD 130.69 Billion in 2024 to USD 238.25 Billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

Pharmaceutical contract development and manufacturing firms provide a range of services to small and large pharmaceutical enterprises under a contract. These services include the production of final dosage forms (FDFs), active ingredients (APIs), drug research & drug discovery services, and biologics. Manufacturers' increasing propensity to use cutting-edge technologies, the expiration of drug patents, rising investments in R&D, the rise in demand for generic medications & biologics, and the COVID-19 pandemic are all factors that have contributed to the growth of the market. Additionally, the market is anticipated to expand because of the rising need for cell and gene treatments, customised medicines, high potency active pharmaceutical ingredients (HPAPIs), and antibody-drug conjugates (ADCs). The adoption of serialisation and a dearth of qualified specialists are two obstacles to this market's expansion, nevertheless.

US Pharmaceutical Contract Development and Manufacturing Market is poised to grow at a sustainable CAGR for the next forecast year.